NASDAQ:OCS Oculis Q2 2025 Earnings Report $17.79 -0.06 (-0.34%) Closing price 04:00 PM EasternExtended Trading$17.80 +0.02 (+0.08%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Oculis EPS ResultsActual EPS-$0.59Consensus EPS -$0.53Beat/MissMissed by -$0.06One Year Ago EPSN/AOculis Revenue ResultsActual Revenue$0.25 millionExpected Revenue$0.14 millionBeat/MissBeat by +$108.00 thousandYoY Revenue GrowthN/AOculis Announcement DetailsQuarterQ2 2025Date8/21/2025TimeAfter Market ClosesConference Call DateThursday, August 21, 2025Conference Call Time4:00PM ETUpcoming EarningsOculis' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Oculis Earnings HeadlinesOculis Holding AG Appoints Mark Kupersmith, M.D. and Sebastian Wolf, M.D., Ph.D. as Chief Medical Advisors in Neuro-Ophthalmology and Ophthalmology RespectivelyAugust 25 at 4:31 AM | quiverquant.comQOculis Holding AG Appoints Mark Kupersmith, M.D. and Sebastian Wolf, M.D., Ph.D. as Chief Medical Advisors to Lead Advances in Neuro-Ophthalmology and OphthalmologyAugust 25 at 4:31 AM | quiverquant.comQMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.August 25 at 2:00 AM | American Alternative (Ad)Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.August 25 at 4:00 AM | globenewswire.comOculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.August 25 at 4:00 AM | globenewswire.comOculis reports Q2 EPS (49c), consensus (43c)August 23 at 8:40 AM | msn.comSee More Oculis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oculis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oculis and other key companies, straight to your email. Email Address About OculisOculis (NASDAQ:OCS), a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.View Oculis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity Upcoming Earnings Bank Of Montreal (8/26/2025)Bank of Nova Scotia (8/26/2025)CrowdStrike (8/27/2025)NVIDIA (8/27/2025)Royal Bank Of Canada (8/27/2025)Snowflake (8/27/2025)Autodesk (8/28/2025)Marvell Technology (8/28/2025)Canadian Imperial Bank of Commerce (8/28/2025)Dell Technologies (8/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access